Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 620

Sort by

Sort Order Select

Journal Articles

FXII inhibition: multipronged benefits

Helen Philippou

Blood (2021) 138 (2): 107–109.

https://doi.org/10.1182/blood.2021011032

Published: 2021

Journal Articles

Pediatric hemophagocytic lymphohistiocytosis

Scott W. Canna, Rebecca A. Marsh

Blood (2020) 135 (16): 1332–1343.

https://doi.org/10.1182/blood.2019000936

Published: 2020

Journal Articles

A Novel Assay of Neutrophil Extracellular Traps (NETs) Formation Independently Predicts DIC and Identifies the Rationale for Anti-IL-8 Therapies

Simon Timothy Abrams, PhD BSc, Ben Morton, MBChB, MD, Yasir Alhamdi, MBChB, PhD, Mohmad Alsabani, Zhenxing Cheng, Steven Lane, PhD, Ingeborg Welters, PhD, Guozheng Wang, MD PhD, Cheng-Hock Toh, MD

Blood (2019) 134 (Supplement_1): 440.

https://doi.org/10.1182/blood-2019-128493

Published: 2019

Journal Articles

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

Andrew H. Wei, Jacqueline S Garcia, MD, Uma Borate, MD, Chun Yew Fong, MBBS,PhDFRACP,FRCPA, Maria R. Baer, MD, Florian Nolte, MD, Pierre Peterlin, Joseph G. Jurcic, MD, Guillermo Garcia-Manero, MD, Wan-Jen Hong, MD, Uwe Platzbecker, Olatoyosi Odenike, MD, Martin Dunbar, DRPH, MS, Ying Zhou, PhD, Jason Harb, PhD, Poonam Tanwani, BSc, Johannes E. Wolff, MD, Meagan Jacoby, MD

Blood (2019) 134 (Supplement_1): 568.

https://doi.org/10.1182/blood-2019-124437

Published: 2019

Journal Articles

The Tissue Factor Pathway Inhibitor Gamma Knockout Mouse Is a Better Model Than the Wild Type Mouse for Studying Tissue Factor-Related Human Diseases

Thomas J. Girard, Nina M. Lasky, Dhanalakshmi S. Anbukumar, George J. Broze, Jr.

Blood (2019) 134 (Supplement_1): 484.

https://doi.org/10.1182/blood-2019-130360

Published: 2019

Journal Articles

Identification of Clonal Immunoglobulin λ Light-Chain Gene Rearrangements in AL Amyloidosis Using Next Generation Sequencing

Blood (2019) 134 (Supplement_1): 1748.

https://doi.org/10.1182/blood-2019-125028

Published: 2019

Journal Articles

A Multi-Center, Multinational, Prospective Observational Registry Study of Defibrotide in Patients Diagnosed with Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT)

Mohamad Mohty, MD PhD, Marta Lisa Battista, Didier Blaise, MD PhD, Elisabetta Calore, MD, Simone Cesaro, Adam Gassas, Natalia Maximova, Katia Perruccio, Cecile Renard, MD, Robert Wynn, Marco Zecca, Myriam Labopin, MD, Raj Hanvesakul, Robert J. Ryan, MS, Fabio Ciceri, MD, Sarah Lawson, MD

Blood (2019) 134 (Supplement_1): 1972.

https://doi.org/10.1182/blood-2019-123529

Published: 2019

Journal Articles

Direct Visualization of Circulating Neutrophil Extracellular Traps Using Cell Fluorescence during Human Septic Shock-Induced Disseminated Intravascular Coagulation

Laure Stiel, MD, Caroline Mayeur-Rousse, MD, Julie Helms, Fehrat Meziani, Laurent Mauvieux, MD PhD

Blood (2019) 134 (Supplement_1): 3583.

https://doi.org/10.1182/blood-2019-124698

Published: 2019

Journal Articles

Thrombomodulin and Endothelial Dysfunction in Sickle Cell Anemia

Maria Armila Ruiz, MS, Binal N. Shah, Jin Han, PharmD, PhD, Rasha Raslan, MD, Victor R Gordeuk, MD, Santosh L. Saraf, MD

Blood (2019) 134 (Supplement_1): 3558.

https://doi.org/10.1182/blood-2019-123862

Published: 2019

Journal Articles

Defibrotide Inhibits Endothelial Cell Injury Induced By Plasmas of Patients with Thrombotic Microangiopathies

Jeffrey Laurence, MD, Sonia Elhadad, PhD

Blood (2019) 134 (Supplement_1): 3676.

https://doi.org/10.1182/blood-2019-124158

Published: 2019

Journal Articles

Rituximab for Preventing Delayed Hemolytic Transfusion Reaction (DHTR) in Sickle CELL Adult Patients: Outcome of Transfusion and SIDE Effects in 58 CASES

Fabian Zanchetta-Balint, France Pirenne, MD PhD, Marc Michel, Armand Mekontso-Dessap, MD PhD, Matthieu Mahevas, MD, Constance Guillaud, MD, Keyvan Razazi, MD, Elena Foïs, MD, Frédéric Galactéros, MD PhD, Pablo Bartolucci, MD PhD, Anoosha Habibi

Blood (2019) 134 (Supplement_1): 3687.

https://doi.org/10.1182/blood-2019-130874

Published: 2019

Journal Articles

Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease

Sheila K Pierson, MS, Laura Katz, MA, Christopher Sheild Nabel, MD PhD, Jason R Ruth, PhD, Sheila Diamond, MS, CGC, Hrishikesh Karvir, PhD, Fanyi Zhang, MS, Manjula P Reddy, MS, MSc, Mary Guilfoyle, MS, Craig Tendler, MD, Frits van Rhee, MD PhD, Philip Beineke, MS, Ana B Oromendia, PhD, David C Fajgenbaum, MDMBA,MSc

Blood (2019) 134 (Supplement_1): 3599.

https://doi.org/10.1182/blood-2019-128284

Published: 2019

Journal Articles

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Constantine S. Tam, MBBS, MD, Gavin Cull, MB, BS, FRACP, FRCPA, Stephen Opat, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA, Aichun Liu, MD, Anna M. Johnston, Weili Zhao, MD PhD, Fernando Roncolato, BMed, FRACP, FRCPA, Sasanka M. Handunnetti, MBBS, FRACP, FRCPA, H. Miles Prince, MBBS (Hons), MD FRACP, FRCPA, AFRCMA, MACD, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Wenyu Li, MD PhD, Ted Shih, PharmD, Xiaoping Zhang, MD MS, Ken Wu, PhD, Yuan Liu, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1594.

https://doi.org/10.1182/blood-2019-125485

Published: 2019

Journal Articles

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Blood (2019) 134 (Supplement_1): 1540.

https://doi.org/10.1182/blood-2019-131367

Published: 2019

Journal Articles

Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia

Andrew T Kuykendall, MD, Anthony Hunter, MD, Ling Zhang, MD, Eric Padron, MD, Chetasi Talati, MD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 2956.

https://doi.org/10.1182/blood-2019-130661

Published: 2019

Journal Articles

Epidemiology and Factors Affecting Mortality of Hospitalized Patients with Disseminated Intravascular Coagulation in the United States

Arya Mariam Roy, MD, Manojna Konda, MD, Akshay Goel, MD, Appalanaidu Sasapu, MD

Blood (2019) 134 (Supplement_1): 2404.

https://doi.org/10.1182/blood-2019-132071

Published: 2019

Journal Articles

Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study

Kenneth I. Ataga, MD, Abdullah Kutlar, MD, Laurie DeBonnett, MD, Jeremie Lincy, Julie Kanter, MD

Blood (2019) 134 (Supplement_1): 2289.

https://doi.org/10.1182/blood-2019-125868

Published: 2019

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Joseph D. Khoury, MD, Sanam Loghavi, MD, Susan O'Brien, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Srdan Verstovsek, MD PhD, Nitin Jain, MD, Madeline Duvic, MD, Phyu Aung, MD, C. Cameron Yin, MD PhD, Sergej Konoplev, Keyur P. Patel, MBBS, PhD, Sherry A. Pierce, BSN, BA, Hannah Beird, PhD, Muzaffar H. Qazilbash, MD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 2723.

https://doi.org/10.1182/blood-2019-132185

Published: 2019

Journal Articles

Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare

Ruth-Anne Langan, BA, Alberto Japp, PhD, Michael Gonzalez, PhD, Rozena Rasheed, BS, Sheila K Pierson, MS, Charlly Kao, PhD, Hakon Hakonarson, MD PhD, Frits van Rhee, MD PhD, Michael Betts, PhD, Taku Kambayashi, MD PhD, David C Fajgenbaum, MDMBA,MSc

Blood (2019) 134 (Supplement_1): 1046.

https://doi.org/10.1182/blood-2019-128994

Published: 2019

Journal Articles

Linking Stored Red Blood Cell Metabolism to Transfusion Recipient Iron Homeostasis Pathophysiology in Critically-Ill Children

Ryan M. Fredericks, MD, Travis Nemkov, PhD, Camilla L'Acqua, MD, Steven L. Spitalnik, MD, Eldad A. Hod, MD, Angelo D'Alessandro, PhD

Blood (2019) 134 (Supplement_1): 1175.

https://doi.org/10.1182/blood-2019-125854

Published: 2019

NARROW

FXII inhibition: multipronged benefits

Pediatric hemophagocytic lymphohistiocytosis

A Novel Assay of Neutrophil Extracellular Traps (NETs) Formation Independently Predicts DIC and Identifies the Rationale for Anti-IL-8 Therapies

A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Treatment-Naïve Patients with Higher-Risk Myelodysplastic Syndrome

The Tissue Factor Pathway Inhibitor Gamma Knockout Mouse Is a Better Model Than the Wild Type Mouse for Studying Tissue Factor-Related Human Diseases

Identification of Clonal Immunoglobulin λ Light-Chain Gene Rearrangements in AL Amyloidosis Using Next Generation Sequencing

A Multi-Center, Multinational, Prospective Observational Registry Study of Defibrotide in Patients Diagnosed with Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Hematopoietic Cell Transplantation (HCT)

Direct Visualization of Circulating Neutrophil Extracellular Traps Using Cell Fluorescence during Human Septic Shock-Induced Disseminated Intravascular Coagulation

Thrombomodulin and Endothelial Dysfunction in Sickle Cell Anemia

Defibrotide Inhibits Endothelial Cell Injury Induced By Plasmas of Patients with Thrombotic Microangiopathies

Rituximab for Preventing Delayed Hemolytic Transfusion Reaction (DHTR) in Sickle CELL Adult Patients: Outcome of Transfusion and SIDE Effects in 58 CASES

Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients Remain

Bone Marrow Mastocytosis Is Independently Associated with Inferior Survival in Chronic Myelomonocytic Leukemia

Epidemiology and Factors Affecting Mortality of Hospitalized Patients with Disseminated Intravascular Coagulation in the United States

Crizanlizumab Treatment Is Associated with Clinically Significant Reductions in Hospitalization in Patients with Sickle Cell Disease: Results from the Sustain Study

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Commonly Presents in the Setting of Prior or Concomitant Hematologic Malignancies (PCHM): Patient Characteristics and Outcomes in the Rapidly Evolving Modern Targeted Therapy Era

Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare

Linking Stored Red Blood Cell Metabolism to Transfusion Recipient Iron Homeostasis Pathophysiology in Critically-Ill Children

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only